{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018894","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.896049+00:00","generated_at":"2026-05-18T06:37:42.457274+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue","bullets":["DSMB recommended study continue without modification after planned interim safety analysis.","~9% of treated women had experienced a pregnancy, consistent with company expectations.","~17% discontinued due to vaginal odor; no serious safety concerns or new tolerability issues.","~115 of target ~250 participants ongoing/completed; final primary endpoint uses Pearl Index.","Bayer can obtain U.S. commercialization rights with $20M payment, plus up to $310M milestones and tiered royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018894","json":"https://secwatch.observer/filing/0001641172-25-018894.json","markdown":"https://secwatch.observer/filing/0001641172-25-018894.md","text":"https://secwatch.observer/filing/0001641172-25-018894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000164117225018894/0001641172-25-018894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000164117225018894/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:37:42.457274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}